At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis
In Brief
A Phase 2 clinical trial evaluating Xolair placebo and Xolair (omalizumab) for Chronic Rhinosinusitis and Nasal Polyps. Completed, enrolled 27 participants across 1 site.
Detailed Summary
The investigators are doing this research study to learn more about a drug called Xolair (omalizumab). The investigators want to see if it is an effective treatment for chronic rhinosinusitis (CRS). Specifically, the investigators want to see whether Xolair will make nasal polyps smaller and less thick, and relieve symptoms in people with CRS. Polyps are abnormal growths of tissue that can grow in the lining of your sinuses (the inside of your nose). The investigators also want to find out if it is safe to use (whether it causes side effects).
Study Details
Timeline
Interventions
two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)